TARRYTOWN, N.Y. and PARIS, April 26, 2019 /PRNewswire/ —
* Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause
* Praluent treatment effect was observed in patients already receiving other lipid-lowering therapies, including maximally-tolerated statins
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Praluent® (alirocumab) to reduce the risk of heart attack, stroke and unstable angina requiring hospitalization in adults with established cardiovascular (CV) disease.
View full press release